Huma Deploys Hi Scribe to Automate Clinical Documentation and Billing Using AI
Hi Scribe is built on top of the Huma AI foundation engine, known as Huma Intelligence (Hi), which also supports Hi Nurse (10X Nurse) and several other AI features. It is powered by insights from over 60 million consultations conducted by eConsult, one of Huma's portfolio companies acquired last year.
Available within the Huma Cloud Platform (HCP), Hi Scribe automates clinical documentation in real-time, automatically generates structured clinical notes and enables direct integration into electronic health record (EHR) systems. It is designed for both in-person and virtual care settings, supporting clinicians across the full spectrum of digital health delivery.
Already launched in the UK to 870 practices (covering 10 million patients) with writeback and coding capabilities for EMIS and SystmOne, the technology leverages Huma's strategic partnership with Google Cloud to deliver secure, scalable, and clinically compliant AI services to frontline healthcare workers.
'Administrative burdens—from documentation to process compliance and accurate billing—are among the greatest challenges facing healthcare systems globally,' said Dan Vahdat, CEO and Founder of Huma. 'Hi Scribe gives clinicians critical time back, allowing them to focus on what matters most: their patients. We're excited to roll this out across the 4,500+ health systems and clinics powered by Huma technologies around the world.'
Regulatory-Compliant, Clinically Integrated
Hi Scribe fully complies with regulations set forth by the UK Medicines and Healthcare products Regulatory Agency (MHRA) as a medical device and is part of Huma's globally compliant, enterprise-grade technology suite. It integrates directly into EHR systems, enabling clinicians to submit documentation seamlessly without disrupting workflow.
As part of a broader care enablement strategy, Hi Scribe empowers clinicians with intelligent tools that reduce documentation burden while enhancing consistency and care quality.
The launch follows recent NHS England guidance supporting the use of AI in clinical documentation and highlights Huma's role in driving innovation across public and private healthcare systems. With documentation consuming up to a third of clinical time globally, Huma is expanding access to Hi Scribe across its international footprint, which includes over 70 countries and 50 million engaged individuals.
'This tool brings clinicians' attention back to their patients,' said Dr. Murray Ellender, Head of UK Healthcare, Huma. 'By leveraging generative AI with strong regulatory governance, we are ensuring safe, effective, and efficient care. We are excited in the near future to start helping care providers with intelligent suggestions for next steps—ensuring that nothing is left unnoticed. We built this product in partnership with Opencast – a leading UK tech consultancy'
'Using Hi Scribe to transcribe my medical notes has transformed my day—saving me 2-3 minutes every consultation, reducing pressure, and letting me focus fully on my patients.' said Dr Ross Dyer-Smith, NHS GP. 'I have more headspace to think, listen, and make decisions. It's brought back more of the most satisfying part of practicing medicine—truly engaging and connecting with my patients.'
U.S. Expansion with Wheel
Huma's partner Wheel, the largest telemedicine provider-as-a-service platform in the U.S., will be among the first to bring Hi Scribe to virtual-first care environments in the U.S. through its Horizon platform.
'Clinicians shouldn't have to choose between delivering great care and managing documentation,' said Michelle Davey, CEO and Founder of Wheel. 'At Wheel, we're always looking for ways to make their jobs easier without adding friction. With Hi Scribe now integrated into Horizon, we're excited to be among the first to bring this kind of transformative AI technology to virtual care in the U.S.— giving our partners and their patients a better experience.'
As Wheel brings Hi Scribe to market, it will be made available to enterprise organizations and digital health partners, expanding access to AI-powered documentation across U.S. virtual care delivery.
Nationwide Rollouts
Huma has also partnered with several countries to roll out this technology across all clinics as part of government-led digital health initiatives. Capturing clinical notes and automatically entering them into EMR systems remains a major challenge for many countries striving to accelerate the digitalization of their healthcare infrastructure.
Ends
Media images are here.
About Huma
Huma owns and operates leading digital and AI-first health products, including Aluna, myGP, GDm, eConsult, and more. All are supported by an AI-driven, software-defined, and federated-enabled operating model.
Its portfolio powers over 4,500 hospitals and clinics, most major pharmaceutical companies, and CROs, with deployments across more than 70 countries. Huma's disease-agnostic cloud platform (HCP) is built for rapid, no-code configuration and seamless AI/ML integration. It has been recognized with FDA 510(k) Class II, EU MDR Class IIb, and other major regulatory certifications. These capabilities enable Huma to quickly launch new use cases and optimize acquired assets. Learn more at huma.com.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Data Broker Industry Analysis Report 2025: Trends and Revenue Projections by Data Types, Pricing Models, Applications, End-Users and Regional Markets to 2034
Data broker market set to grow at a CAGR of 9.8%, driven by personalized data demand and e-commerce expansion Data Broker Market Dublin, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The "Data Broker Market Report 2025" has been added to offering. The data broker market is projected to experience significant growth, expanding from $303.11 billion in 2024 to $332.89 billion in 2025, with a compound annual growth rate (CAGR) of 9.8%. This expansion is driven by increasing demand for personalized data insights, data-driven decision-making strategies, and a rise in IoT adoption. These factors, coupled with the growing number of internet users and smartphones, are enhancing market dynamics. Looking forward, the market is expected to reach $479.73 billion by 2029, with a CAGR of 9.6%. Key drivers include the widespread adoption of social media, the booming e-commerce sector, and rapid industrialization. The market is further influenced by the need for targeted marketing strategies and the proliferation of connected devices. Emerging technologies and business models, along with advancements in big data analytics and AI, are set to redefine the market landscape. E-commerce plays a pivotal role in this growth trajectory. Enhanced internet penetration, smartphone adoption, and consumer preferences for convenience, alongside digital payment advancements and improved delivery networks, are fueling e-commerce expansion. This is boosting the demand for data brokers who provide e-commerce businesses with insights into customer behavior, aiding in improved targeting, personalization, and fraud prevention. E-commerce sales in 2024 soared to $1.19 trillion, marking an 8.1% rise from 2023, according to the US Census Bureau. Leading companies in the data broker domain, such as Experian Plc, are pioneering innovative services like data onboarding, which enhances data integration and compliance. Experian's third-party data marketplace launched in January 2025 exemplifies this trend, enabling marketers to seamlessly blend third-party and first-party data, improving audience segmentation and campaign personalization. Acxiom LLC's collaboration with Amazon Advertising in March 2023 highlights the industry's focus on leveraging data-driven insights to enhance privacy-conscious marketing efforts across multiple channels. Key market players include IBM, Oracle, Bloomberg Finance L.P., LexisNexis Risk Solutions, Thomson Reuters, Experian Information Solutions Inc., and Equifax Inc, among others. North America was the largest market in 2024, with Asia-Pacific poised to record the fastest growth over the forecast period, covering regions from Western Europe to the Middle East. The market report provides comprehensive insights into global trends, regional shares, competitive landscape, market segments, and future opportunities. The data broker market thrives on revenues generated through services like audience segmentation, targeting, lead generation, business intelligence, and analytics. Regional market values represent consumption revenues derived within a specified geography. Reasons to Purchase: Acquire a global perspective with a report spanning 15 geographies. Evaluate the effects of macro factors such as conflicts, pandemics, economic fluctuations, and political changes. Develop targeted regional and country strategies through detailed local data analysis. Identify key investment opportunities in growth segments. Gain competitive advantage using forecast data and market drivers. Understand customer preferences through up-to-date market share insights. Benchmark performance against major competitors with high-quality data and analysis. Receive timely report updates with data available in Excel for enhanced analysis. Market Scope Markets Covered: Data Types: Unstructured, Structured, and Custom Structure Data. Pricing Models: Subscription Paid, Pay Per Use Paid, Hybrid Paid Models. Applications: Marketing and Advertising, Fraud Detection, Risk Management, and more. End-Users: BFSI, Retail, Automotive, Construction, among others. Subsegments: Data categories range from Social Media and Web Content Data to Industry-Specific and Predictive Analytics Data. Key Companies Profiled: Notable companies such as IBM, Oracle Corporation, Bloomberg Finance L.P., and others. Regions and Countries: Extensive coverage of Asia-Pacific, Europe, North America, and other regions, detailing major markets like the USA, China, India, and more. Time Series: A thorough timeline with five years of historical and ten years of forecast data. Data Insights: Includes relationships to related markets, GDP correlations, and consumer spending data. Data Segmentation: Covers market share, competitor analysis, and historical versus forecasted market data. Key Attributes Report Attribute Details No. of Pages 175 Forecast Period 2025-2029 Estimated Market Value (USD) in 2025 $332.89 Billion Forecasted Market Value (USD) by 2029 $479.73 Billion Compound Annual Growth Rate 9.6% Regions Covered Global The companies featured in this Data Broker market report include: International Business Machines Corporation (IBM) Oracle Corporation Bloomberg Finance L.P. LexisNexis Risk Solutions Thomson Reuters Experian Information Solutions Inc. Wolters Kluwer N.V. Equifax Inc TransUnion LLC NielsenIQ Dun & Bradstreet Inc. Fair Isaac and Company CoreLogic Acxiom LLC Data Axle Epsilon Data Management LLC Lotame Solutions Inc. Intelius LLC. Whitepages Inc. Ignite Enterprise Software Solutions LLC. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Data Broker Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900登入存取你的投資組合
Yahoo
3 hours ago
- Yahoo
iQIYI Announces Second Quarter 2025 Financial Results
BEIJING, Aug. 20, 2025 (GLOBE NEWSWIRE) -- iQIYI, Inc. (Nasdaq: IQ) ('iQIYI' or the 'Company'), a leading provider of online entertainment video services in China, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Total revenues were RMB6.63 billion (US$925.3 million1), decreasing 11% year over year. Operating loss was RMB46.2 million (US$6.4 million) and operating loss margin was 1%, compared to operating income of RMB342.1 million and operating income margin of 5% in the same period in 2024. Non-GAAP operating income2 was RMB58.7 million (US$8.2 million) and non-GAAP operating income margin was 1%, compared to non-GAAP operating income of RMB501.4 million and non-GAAP operating income margin of 7% in the same period in 2024. Net loss attributable to iQIYI was RMB133.7 million (US$18.7 million), compared to net income attributable to iQIYI of RMB68.7 million in the same period in 2024. Non-GAAP net income attributable to iQIYI2 was RMB14.7 million (US$2.0 million), compared to non-GAAP net income attributable to iQIYI of RMB246.9 million in the same period in 2024. 'During the second quarter and into the summer season, we delivered a series of blockbusters and secured the top market share in total drama viewership, according to Enlightent data,' commented Mr. Yu Gong, Founder, Director, and Chief Executive Officer of iQIYI. 'Meanwhile, we are focusing on innovation and investing in key growth areas such as AI applications, micro dramas, experience business, and global expansion, all with the goal of driving sustainable, long-term success.' 'We effectively managed our resources and optimized our capital structure, with net interest expense³ consistently declining over the last seven consecutive quarters. This better positions us for long-term value creation,' commented Mr. Jun Wang, Chief Financial Officer of iQIYI. Second Quarter 2025 Financial Highlights Three Months Ended (Amounts in thousands of Renminbi ('RMB'), except for per ADS data, unaudited) June 30, March 31, June 30, 2024 2025 2025 RMB RMB RMB Total revenues 7,438,785 7,186,469 6,628,248 Operating income/(loss) 342,093 341,897 (46,168 ) Operating income (non-GAAP) 501,417 458,535 58,678 Net income/(loss) attributable to iQIYI, Inc. 68,685 182,145 (133,708 ) Net income attributable to iQIYI, Inc. (non-GAAP) 246,914 304,420 14,652 Diluted net income/(loss) per ADS 0.07 0.19 (0.14 ) Diluted net income per ADS (non-GAAP)2 0.25 0.31 0.02 Footnotes: [1] Unless otherwise noted, RMB to USD was converted at an exchange rate of RMB7.1636 as of June 30, 2025, as set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System. Translations are provided solely for the convenience of the reader.[2] Non-GAAP measures are defined in the Non-GAAP Financial Measures section (see also 'Reconciliations of Non-GAAP Financial Measures to the Nearest Comparable GAAP Measures' for more details).[3] Net interest expense refers to the net amount of interest expense and interest income, both of which are presented in the Condensed Consolidated Statements of Income/(Loss). Second Quarter 2025 Financial Results Total revenues reached RMB6.63 billion (US$925.3 million), decreasing 11% year over year. Membership services revenue was RMB4.09 billion (US$571.0 million), decreasing 9% year over year, primarily due to a lighter content slate compared to the same period last year. Online advertising services revenue was RMB1.27 billion (US$177.6 million), decreasing 13% year over year. During the quarter, some advertisers adjusted their advertising and promotion strategies in response to macro pressures. Content distribution revenue was RMB436.6 million (US$60.9 million), decreasing 37% year over year, primarily due to the decrease in barter transactions and, to a lesser extent, the decrease in cash transactions. Other revenues were RMB829.3 million (US$115.8 million), increasing 6% year over year. Cost of revenues was RMB5.29 billion (US$738.9 million), decreasing 7% year over year. Content costs as a component of cost of revenues were RMB3.78 billion (US$528.0 million), decreasing 8% year over year. The decrease in content cost was primarily due to a lighter content slate in the quarter. Selling, general and administrative expenses were RMB959.6 million (US$134.0 million), decreasing 1% year over year. Research and development expenses were RMB421.9 million (US$58.9 million), decreasing 6% year over year. Operating loss was RMB46.2 million (US$6.4 million), compared to operating income of RMB342.1 million in the same period in 2024. Operating loss margin was 1%, compared to operating income margin of 5% in the same period in 2024. Non-GAAP operating income was RMB58.7 million (US$8.2 million), compared to non-GAAP operating income of RMB501.4 million in the same period in 2024. Non-GAAP operating income margin was 1%, compared to non-GAAP operating income margin of 7% in the same period in 2024. Total other expense was RMB61.9 million (US$8.6 million), decreasing 74% year over year, primarily due to gain from foreign exchange. Loss before income taxes was RMB108.1 million (US$15.1 million), compared to income before income taxes of RMB101.7 million in the same period in 2024. Income tax expense was RMB27.2 million (US$3.8 million), compared to income tax expense of RMB25.7 million in the same period in 2024. Net loss attributable to iQIYI was RMB133.7 million (US$18.7 million), compared to net income attributable to iQIYI of RMB68.7 million in the same period in 2024. Diluted net loss attributable to iQIYI per ADS was RMB0.14 (US$0.02) for the second quarter of 2025, compared to diluted net income attributable to iQIYI per ADS of RMB0.07 in the same period of 2024. Non-GAAP net income attributable to iQIYI was RMB14.7 million (US$2.0 million), compared to non-GAAP net income attributable to iQIYI of RMB246.9 million in the same period in 2024. Non-GAAP diluted net income attributable to iQIYI per ADS was RMB0.02 (US$0.00), compared to non-GAAP diluted net income attributable to iQIYI per ADS of RMB0.25 in the same period of 2024. Net cash used for operating activities was RMB12.7 million (US$1.8 million), compared to net cash provided by operating activities of RM410.8 million in the same period of 2024. Free cash flow was negative RMB34.1 million (negative US$4.8 million), compared to free cash flow of RMB382.5 million in the same period of 2024. As of June 30, 2025, the Company had cash, cash equivalents, restricted cash, short-term investments and long-term restricted cash included in prepayments and other assets of RMB5.06 billion (US$705.7 million). In addition, as of the same date, the Company had a loan of US$522.5 million to PAG, recorded under the line item of amounts due from related parties. In the second quarter of 2025, the Company had repurchased an aggregate principal amount of US$85.0 million of the 2028 Notes for cash. As of June 30, 2025, US$0.1 million principal amount of the 2026 Notes, US$522.5 million principal amount of the PAG Notes, US$208.1 million principal amount of the 2028 Notes, and US$350.0 million principal amount of the 2030 Notes remained outstanding. Conference Call Information iQIYI's management will hold an earnings conference call at 7:00 AM on August 20, 2025, U.S. Eastern Time (7:00 PM on August 20, 2025, Beijing Time). Please register in advance of the conference using the link provided below. Upon registering, you will be provided with participant dial-in numbers, passcode and unique access PIN by a calendar invite. Participant Online Registration: It will automatically direct you to the registration page of "iQIYI Second Quarter 2025 Earnings Conference Call", where you may fill in your details for RSVP. In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration. A telephone replay of the call will be available after the conclusion of the conference call through August 27, 2025. Dial-in numbers for the replay are as follows: International Dial-in +1 855 883 1031Passcode: 10049037 A live and archived webcast of the conference call will be available at About iQIYI, Inc. iQIYI, Inc. is a leading provider of online entertainment video services in China. It combines creative talent with technology to foster an environment for continuous innovation and the production of blockbuster content. It produces, aggregates and distributes a wide variety of professionally produced content, as well as a broad spectrum of other video content in a variety of formats. iQIYI distinguishes itself in the online entertainment industry by its leading technology platform powered by advanced AI, big data analytics and other core proprietary technologies. Over time, iQIYI has built a massive user base and developed a diversified monetization model including membership services, online advertising services, content distribution, online games, IP licensing, talent agency, online literature, etc. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'confident' and similar statements. Among other things, the quotations from management in this announcement, as well as iQIYI's strategic and operational plans, contain forward-looking statements. iQIYI may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about iQIYI's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: iQIYI's strategies; iQIYI's future business development, financial condition and results of operations; iQIYI's ability to retain and increase the number of users, members and advertising customers, and expand its service offerings; competition in the online entertainment industry; changes in iQIYI's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online entertainment industry, general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and iQIYI undertakes no duty to update such information, except as required under applicable law. Non-GAAP Financial Measures To supplement iQIYI's consolidated financial results presented in accordance with GAAP, iQIYI uses the following non-GAAP financial measures: non-GAAP operating income, non-GAAP operating income margin, non-GAAP net income/(loss) attributable to iQIYI, non-GAAP diluted net income/(loss) attributable to iQIYI per ADS and free cash flow. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. iQIYI believes that these non-GAAP financial measures provide meaningful supplemental information regarding its operating performance by excluding certain items that may not be indicative of its business operating results, such as operating performance excluding non-cash charges or non-operating in nature. The Company believes that both management and investors benefit from referring to the non-GAAP financial measures in assessing its performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to iQIYI's historical operating performance. The Company believes the non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using these non-GAAP financial measures is that the non-GAAP measures exclude certain items that have been and will continue to be for the foreseeable future a significant component in the Company's results of operations. These non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to the Company's data. Non-GAAP operating income represents operating income excluding share-based compensation expenses, amortization of intangible assets resulting from business combinations. Non-GAAP net income/(loss) attributable to iQIYI, Inc. represents net income/(loss) attributable to iQIYI, Inc. excluding share-based compensation expenses, amortization of intangible assets resulting from business combinations, disposal gain or loss, impairment of long-term investments, fair value change of long-term investments, adjusted for related income tax effects. iQIYI's share of equity method investments for these non-GAAP reconciling items, primarily amortization and impairment of intangible assets not on the investees' books, accretion of their redeemable non-controlling interests, and the gain or loss associated with the issuance of shares by the investees at a price higher or lower than the carrying value per share, adjusted for related income tax effects, are also excluded. Non-GAAP diluted net income/(loss) per ADS represents diluted net income/(loss) per ADS calculated by dividing non-GAAP net income/(loss) attributable to iQIYI, Inc, by the weighted average number of ordinary shares expressed in ADS. Free cash flow represents net cash provided by operating activities less capital expenditures. For more information, please contact: Investor RelationsiQIYI, Consolidated Statements of Income/(Loss) (In RMB thousands, except for number of shares and per share data) Three Months Ended Six Months Ended June 30, March 31, June 30, June 30, June 30, 2024 2025 2025 2024 2025 RMB RMB RMB RMB RMB (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Revenues: Membership services 4,495,310 4,399,010 4,090,126 9,294,171 8,489,136 Online advertising services 1,461,367 1,327,827 1,272,198 2,943,419 2,600,025 Content distribution 698,175 628,743 436,578 1,626,184 1,065,321 Others 783,933 830,889 829,346 1,502,366 1,660,235 Total revenues 7,438,785 7,186,469 6,628,248 15,366,140 13,814,717 Operating costs and expenses: Cost of revenues (5,678,342 ) (5,406,341 ) (5,292,894 ) (11,309,581 ) (10,699,235 ) Selling, general and administrative (969,673 ) (1,025,742 ) (959,604 ) (1,891,708 ) (1,985,346 ) Research and development (448,677 ) (412,489 ) (421,918 ) (878,005 ) (834,407 ) Total operating costs and expenses (7,096,692 ) (6,844,572 ) (6,674,416 ) (14,079,294 ) (13,518,988 ) Operating income/(loss) 342,093 341,897 (46,168 ) 1,286,846 295,729 Other income/(expenses): Interest income 68,688 78,756 87,779 127,428 166,535 Interest expenses (288,162 ) (233,429 ) (235,267 ) (570,297 ) (468,696 ) Foreign exchange gain/(loss), net (51,338 ) 41,889 100,811 (82,889 ) 142,700 Share of gains/(losses) from equity method investments (2,100 ) (3,617 ) (1,086 ) 11,414 (4,703 ) Others, net 32,476 1,724 (14,134 ) 12,617 (12,410 ) Total other expense, net (240,436 ) (114,677 ) (61,897 ) (501,727 ) (176,574 ) Income/(loss) before income taxes 101,657 227,220 (108,065 ) 785,119 119,155 Income tax expense (25,741 ) (41,590 ) (27,155 ) (43,374 ) (68,745 ) Net income/(loss) 75,916 185,630 (135,220 ) 741,745 50,410 Less: Net income/(loss) attributable to noncontrolling interests 7,231 3,485 (1,512 ) 17,743 1,973 Net income/(loss) attributable to iQIYI, Inc. 68,685 182,145 (133,708 ) 724,002 48,437 Net income/(loss) attributable to ordinary shareholders 68,685 182,145 (133,708 ) 724,002 48,437 Net income/(loss) per share for Class A and Class B ordinary shares: Basic 0.01 0.03 (0.02 ) 0.11 0.01 Diluted 0.01 0.03 (0.02 ) 0.11 0.01 Net income/(loss) per ADS (1 ADS equals 7 Class A ordinary shares): Basic 0.07 0.19 (0.14 ) 0.75 0.05 Diluted 0.07 0.19 (0.14 ) 0.74 0.05 Weighted average number of Class A and Class B ordinary shares used in net income/(loss) per share computation: Basic 6,725,978,497 6,740,810,595 6,743,563,754 6,721,815,708 6,742,194,780 Diluted 6,857,915,450 6,780,303,294 6,743,563,754 6,822,994,286 6,780,167,606iQIYI, Consolidated Balance Sheets (In RMB thousands, except for number of shares and per share data) December 31, June 30, 2024 2025 RMB RMB (Unaudited) ASSETS Current assets: Cash and cash equivalents 3,529,679 3,329,708 Restricted cash - 2,062 Short-term investments 941,610 917,165 Accounts receivable, net 2,191,178 2,191,126 Prepayments and other assets 2,192,928 2,172,378 Amounts due from related parties 283,123 264,262 Licensed copyrights, net 388,718 579,132 Total current assets 9,527,236 9,455,833 Non-current assets: Fixed assets, net 877,982 839,284 Long-term investments 2,108,477 1,978,055 Deferred tax assts, net 23,536 21,197 Licensed copyrights, net 6,930,053 6,669,903 Intangible assets, net 289,861 252,596 Produced content, net 14,707,869 14,484,001 Prepayments and other assets 2,913,919 4,470,231 Operating lease assets 609,832 513,704 Goodwill 3,820,823 3,820,823 Amounts due from related parties 3,950,937 3,859,086 Total non-current assets 36,233,289 36,908,880 Total assets 45,760,525 46,364,713 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts and notes payable 6,482,209 6,956,061 Amounts due to related parties 3,239,036 3,361,596 Customer advances and deferred revenue 4,403,686 4,457,113 Convertible senior notes, current portion 242,460 1,483,936 Short-term loans 3,786,901 2,757,119 Long-term loans, current portion 167,987 717,991 Operating lease liabilities, current portion 96,675 81,728 Accrued expenses and other liabilities 3,058,379 2,725,586 Total current liabilities 21,477,333 22,541,130 Non-current liabilities: Long-term loans 1,036,835 2,300,177 Convertible senior notes 8,350,570 6,739,446 Amounts due to related parties 59,226 49,057 Operating lease liabilities 461,974 363,730 Other non-current liabilities 1,000,823 860,803 Total non-current liabilities 10,909,428 10,313,213 Total liabilities 32,386,761 32,854,343 Shareholders' equity: Class A ordinary shares 238 238 Class B ordinary shares 193 193 Additional paid-in capital 55,623,841 55,842,259 Accumulated deficit (43,809,369 ) (43,760,932 ) Accumulated other comprehensive income 1,550,523 1,438,027 Non-controlling interests 8,338 (9,415 ) Total shareholders' equity 13,373,764 13,510,370 Total liabilities and shareholders' equity 45,760,525 46,364,713 iQIYI, Consolidated Statements of Cash Flows (In RMB thousands, except for number of shares and per share data) Three Months Ended June 30, March 31, June 30, 2024 2025 2025 RMB RMB RMB (Unaudited) (Unaudited) (Unaudited) Net cash provided by/(used for) operating activities 410,752 338,950 (12,731 ) Net cash provided by/(used for) investing activities (1,2) 336,256 (30,136 ) (114,005 ) Net cash provided by/(used for) financing activities 865,894 860,477 (465,256 ) Effect of exchange rate changes on cash, cash equivalents and restricted cash 23,113 (1,232 ) (27,881 ) Net increase/(decrease) in cash, cash equivalents and restricted cash 1,636,015 1,168,059 (619,873 ) Cash, cash equivalents and restricted cash at the beginning of the period 6,271,368 3,590,331 4,758,390 Cash, cash equivalents and restricted cash at the end of the period 7,907,383 4,758,390 4,138,517 Reconciliation of cash and cash equivalents and restricted cash: Cash and cash equivalents 6,301,808 4,320,028 3,329,708 Restricted cash - 1,899 2,062 Long-term restricted cash 1,605,575 436,463 806,747 Total cash and cash equivalents and restricted cash shown in the statements of cash flows 7,907,383 4,758,390 4,138,517 Net cash provided by/(used for) operating activities 410,752 338,950 (12,731 ) Less: Capital expenditures (2) (28,299 ) (31,252 ) (21,410 ) Free cash flow 382,453 307,698 (34,141 ) (1) Net cash provided by or used for investing activities primarily consists of net cash flows from investing in debt securities, purchase of long-term investments and capital expenditures.(2) Capital expenditures are incurred primarily in connection with construction in process, computers and of Non-GAAP Financial Measures to the Nearest Comparable GAAP Measures(Amounts in thousands of Renminbi ('RMB'), except for per ADS information, unaudited) Three Months Ended June 30, March 31, June 30, 2024 2025 2025 RMB RMB RMB Operating income/(loss) 342,093 341,897 (46,168 ) Add: Share-based compensation expenses 157,791 115,105 103,313 Add: Amortization of intangible assets(1) 1,533 1,533 1,533 Operating income (non-GAAP) 501,417 458,535 58,678 Net income/(loss) attributable to iQIYI, Inc. 68,685 182,145 (133,708 ) Add: Share-based compensation expenses 157,791 115,105 103,313 Add: Amortization of intangible assets(1) 1,533 1,533 1,533 Add: Impairment of long-term investments 16,591 2,000 25,950 Add: Fair value loss/(gain) of long-term investments 2,577 (1,740 ) 17,564 Add: Reconciling items on equity method investments - 5,377 - Add: Tax effects on non-GAAP adjustments(2) (263 ) - - Net income attributable to iQIYI, Inc. (non-GAAP) 246,914 304,420 14,652 Diluted net income/(loss) per ADS 0.07 0.19 (0.14 ) Add: Non-GAAP adjustments to earnings per ADS 0.18 0.12 0.16 Diluted net income per ADS (non-GAAP) 0.25 0.31 0.02 (1) This represents amortization of intangible assets resulting from business combinations.(2) This represents tax impact of all relevant non-GAAP in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
